NanoViricides Reports that its Director Dr. Milton Boniuk, a Director, Has Invested $5M into the Company in a Convertible Debenture
Published: July 2, 2014 7:00 a.m. ET
WEST HAVEN, Conn., Jul 02, 2014 (BUSINESS WIRE) -- NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”) reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company, has invested $5M in the Company in the form of a convertible debenture (the “Debenture”).
Dr. Boniuk said that his confidence in the Company has only continued to grow as he sees the Company’s management and execution now from a closer perspective, in his role as a Director.
Professor Boniuk has also invested in the Company in earlier rounds of financing. The new financing brings the total financing provided by him to $12 Million to date. These investments were made both personally as well as from his charitable foundation and other interests. Professor Boniuk joined the Company’s Board as an independent director in May 2013, at the request of the Company’s executives.
“My belief that the Company’s potential is nothing short of amazing has only become stronger as I become more familiar with the Company’s technology, programs, and achievements,” said Dr. Boniuk when asked about his continuing investments into the Company.
And here is a link to the form 4 for the recent open market purchases that you seemed to miss,
News 
Market Data 
Discover 
